Dr. Christopher D. Bahl received his doctoral degree in Biochemistry from Geisel School of Medicine at Dartmouth. He had continued postdoctoral research with Dr. David Baker at the University of Washington. Dr. Bahl is currently the Head of Protein Design at the Institute of Protein Innovation. Chris is leading a group focusing on leveraging de novo computational design to develop allosteric modulators and ligands for G protein-coupled receptors (GPCRs); and advancing protein design field through innovative advancements in methodology by implementing computational cloud infrastructure and novel design algorithms. Meantime he’s optimizing methods for high-throughput protein production and characterization in the laboratory.
Research Area and Skills
Recognize this scientist’s Expertise for their contribution in your research
Protein Engineering 7 Bioinformatics 4 Protein Design 3 Protein Characterization 2
Some common medicines, such as insulin, are made of proteins so large and fragile that they need to be injected instead of ingested as pills. But a new generation of medicine -- made from smaller, more durable proteins known as peptides -- is on its way!
Buchko GW, Pulavarti SVSRK, Ovchinnikov V, et al. Cytosolic expression, solution structures, and molecular dynamics simulation of genetically encodable disulfide-rich de novo designed peptides. Protein Sci. 2018;27(9):1611-1623.
Bahl CD, St laurent JD, Karthikeyan RS, et al. The cif Virulence Factor Gene Is Present in Isolates From Patients With Pseudomonas aeruginosa Keratitis. Cornea. 2017;36(3):358-362.
Chevalier A, Silva DA, Rocklin GJ, et al. Massively parallel de novo protein design for targeted therapeutics. Nature. 2017;550(7674):74-79.